Cariprazine, A Dopamine D2/D3 Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer

Cariprazine, A Dopamine D2/D3 Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer

Multidrug resistance (MDR) is a continuing clinical problem that limits the efficacy of chemotherapy in cancer. The over expression of the ATP-binding cassette (ABC) family G2 (ABCG2) transporter is one of the main mechanisms that mediates MDR in cancer. Molecular modeling data indicated that caripr...

Full description

Bibliographic Details
Main Authors:	Noor Hussein, Charles R. Ashby, Haneen Amawi, Angelique Nyinawabera, Atul Vij, Vishwa M. Khare, Chandrabose Karthikeyan, Amit K. Tiwari
Format:	Article
Language:	English
Published:	MDPI AG 2018-09-01
Series:	Cancers
Subjects:	ABCG2 Cariprazine Colon cancer Lung cancer Dopamine D3-preferring D2/D3 receptor partial Multidrug resistance
Online Access:	http://www.mdpi.com/2072-6694/10/9/308

Similar Items

Update on schizophrenia and bipolar disorder: focus on cariprazine
by: Roberts RJ, et al.
Published: (2016-07-01)

Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)
by: Nakamura T, et al.
Published: (2016-01-01)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
by: Kiss B, et al.
Published: (2019-09-01)

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
by: Balázs Szatmári, et al.
Published: (2020-03-01)

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
by: Citrome L
Published: (2018-10-01)

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
by: Aleksandr M. Reznik, et al.
Published: (2020-10-01)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
by: Aubel T
Published: (2021-07-01)

Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
by: Dorte Lisbet Nielsen, et al.
Published: (2017-09-01)

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
by: Montes JM, et al.
Published: (2021-02-01)

Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data
by: Tohen M
Published: (2021-05-01)

Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
by: Yongchao Zhang, et al.
Published: (2020-11-01)

The study of drug resistance properties of ABCG2 (ATP-binding cassette G2) in contact with thymoquinone, gallic acid, and hesperetin antioxidants
by: Javad Saffari_Chaleshtori, et al.
Published: (2019-03-01)

Le transporteur ABCG2 de multiples drogues : rôle d’une séquence spécifique et recherche d’inhibiteurs sélectifs
by: Macalou, Sira
Published: (2009)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
by: Correll CU, et al.
Published: (2019-08-01)

AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer
by: Kun Liu, et al.
Published: (2021-05-01)

OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance
by: Yuqi Yang, et al.
Published: (2021-02-01)

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer
by: Jesper Andreas Palshof, et al.
Published: (2020-07-01)

Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive Dysfunction
by: Jose Rodriguez Cruz, et al.
Published: (2021-08-01)

Cellular Processing of the ABCG2 Transporter—Potential Effects on Gout and Drug Metabolism
by: Orsolya Mózner, et al.
Published: (2019-10-01)

High expression of ABCG2 is associated with chemotherapy resistance of osteosarcoma
by: Hao Shu, et al.
Published: (2021-01-01)

Estradiol regulates intestinal ABCG2 to promote urate excretion via the PI3K/Akt pathway
by: Lei Liu, et al.
Published: (2021-06-01)

Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel
by: Andrea Fagiolini, et al.
Published: (2020-09-01)

Le transporteur de médicaments anticancéreux, ABCG2, et son implication dans la chimiorésistance : étude structurale et mécanistique
by: Kassis, Josiane
Published: (2019)

A case series of serious and unexpected adverse drug reactions under treatment with cariprazine
by: Johannes Heck, et al.
Published: (2021-05-01)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
by: Barabássy Á, et al.
Published: (2021-04-01)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
by: Barabássy Á, et al.
Published: (2021-05-01)

Expression of ABCG2 (BCRP) in mouse models with enhanced erythropoiesis
by: Gladys Oluyemisi Latunde-Dada, et al.
Published: (2014-06-01)

PCI29732, a Bruton’s Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells
by: Chunlei Ge, et al.
Published: (2018-08-01)

Effect on Body Weight and Adipose Tissue by Cariprazine: A Head-to-Head Comparison Study to Olanzapine and Aripiprazole in Rats
by: László-István Bába, et al.
Published: (2020-10-01)

ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches
by: Cleophas MC, et al.
Published: (2017-04-01)

Effects of High-Intensity Resistance Training and Aerobic Exercise on Expression of ABCG4, ABCG5 and ABCG8 Genes in Female Athletes
by: Reza Bagheri, et al.
Published: (2020-05-01)

The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients
by: Blanka Stiburkova, et al.
Published: (2019-03-01)

ABCG2 Overexpression Contributes to Pevonedistat Resistance
by: Rishil J. Kathawala, et al.
Published: (2020-02-01)

Early-Onset Schizophrenia With Predominantly Negative Symptoms: A Case Study of a Drug-Naive Female Patient Treated With Cariprazine
by: Maria Judit Molnar, et al.
Published: (2020-04-01)

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
by: Henry A. Nasrallah, et al.
Published: (2017-08-01)

Lansoprazole and its Metabolites in the Treatment of TNBC and the Contribution of ABCG2 to CC-115 Resistance
by: Beebe, Jennifer Diane
Published: (2019)

Evidence of progenitor cells in the adult human cochlea: sphere formation and identification of ABCG2
by: Milene Massucci-Bissoli, et al.

ABCG2 is a potential prognostic marker of overall survival in patients with clear cell renal cell carcinoma
by: Haofei Wang, et al.
Published: (2017-03-01)

Protein Arginine Methyltransferase 3 Enhances Chemoresistance in Pancreatic Cancer by Methylating hnRNPA1 to Increase ABCG2 Expression
by: Ming-Chuan Hsu, et al.
Published: (2018-12-01)

Functional Polymorphisms of the ABCG2 Gene Are Associated with Gout Disease in the Chinese Han Male Population
by: Danqiu Zhou, et al.
Published: (2014-05-01)